FDA Advisory Committee Members Raise Concerns About Aducanumab

Video

In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020.

In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020. In an interview with Pharmacy Times, Pamela Spicer, senior analyst with Datamonitor at Informa Pharma Intelligence, explained their apprehension.

Notably, Spicer said the FDA worked more closely with Biogen on the approval than they typically would during other review processes. She said that because of this, some advisory committee members questioned the agency's objectivity.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.